Pfizer to invest $120M, add jobs in Paxlovid production push

After initially struggling to meet demand for Paxlovid, Pfizer is putting significant resources toward expanding an important manufacturing plant in Michigan.

By Delilah Alvarado • June 7, 2022

Why choosing the right primary container is crucial

New mRNA technology: identifying the right drug containment solution is more important than ever.

May 16, 2022

Novartis suspends production of two radiopharmaceutical drugs over quality concerns

Due to potential issues in manufacturing, the pharma is halting deliveries of two cancer drugs, Lutathera and Pluvicto, in the U.S. and Canada, a setback for a business in which the company has invested heavily.  

By Ned Pagliarulo • May 6, 2022

Seagen to expand, add jobs with new cancer drug factory

While some biotechs are restructuring amid a market downturn, SeaGen plans to add 200 positions through a large manufacturing plant that should be operational in 2024.

By Jacob Bell • April 21, 2022

Gilead gets cell therapy boost with FDA clearance of Maryland factory

The new site in Maryland will be used to produce Yescarta, which this month won an expanded approval that substantially widens its market.

By Ned Pagliarulo • April 19, 2022

Sanofi API spinout takes step toward market listing

French regulators have approved plans by Sanofi to list the new EUROAPI business on Euronext Paris beginning May 6.

By Ned Pagliarulo • April 1, 2022

Novartis turns cell therapy skill into contract manufacturing deal

In an unusual arrangement, the Swiss pharma will make Carisma Therapeutics' experimental cell therapy at its Morris Plains factory, part of its plans to build up a CMO business.

By Ned Pagliarulo • March 10, 2022

Novo sees fast growth ahead of obesity drugs despite production hurdles

The Danish drugmaker aims to triple sales of its weight loss treatments Wegovy and Saxenda by 2025. But first, Novo needs to resolve manufacturing constraints that have slowed the former drug's launch. 

By Ned Pagliarulo • March 4, 2022

Atara sells cell therapy plant to Fujifilm for $100M

The site, which specializes in manufacturing off-the-shelf immunotherapies, was once a key asset for Atara. New owner Fujifilm will still supply the biotech under a long-term agreement.

By Ned Pagliarulo • Jan. 27, 2022

3 ways an IWMS can help streamline your manufacturing operations

Manage, maintain and optimize all the tasks, duties and goals that fall under the umbrella of your workplace.

Jan. 24, 2022

Generic manufacturers sign pact to supply Merck COVID pill to lower-income countries

The licenses will help make molnupiravir available to people in more than 100 countries, giving public health authorities a needed tool despite the drug's limited effectiveness.

By Jonathan Gardner • Jan. 20, 2022

German Merck buys manufacturer of key component in mRNA medicines

Merck KGaA is buying Indianapolis-based Exelead, a specialist in the lipid nanoparticles used to ferry mRNA into the body, for $780 million in cash. 

By Ned Pagliarulo • Jan. 6, 2022

Pfizer opens gene therapy plant in $800M North Carolina expansion

The new facility cost nearly $70 million to build, and is part of a major push by the pharma giant to become a leader in genetic medicine manufacturing.

By Kristin Jensen • Dec. 16, 2021

Moderna cuts vaccine sales, delivery targets for 2021

The biotech now expects to deliver between 700 million and 800 million doses this year, down from a previous forecast of 800 million to 1 billion.

By Ned Pagliarulo • Nov. 4, 2021

Gates Foundation pledges $120M to bring Merck COVID-19 drug to lower-income countries

Anticipating regulatory clearance of the pill, the group aims to speed access by investing in the manufacturing of generic versions of the drug.

By Kristin Jensen • Oct. 20, 2021

Emerging therapeutic oligonucleotides – analytical challenges accepted

A relatively new class of parenteral drug products on the market - therapeutic oligonucleotides – poses new challenges to the pharmaceutical manufacturing process.

By Alexandra H. Heussner, Ph. D., Laboratory Manager ASL, and Melanie Zerulla-Wernitz, Ph. D., Head of ASL, Development Service, Vetter Pharma-Fertigung GmbH & Co. KG • Oct. 18, 2021

Under pressure to share technology, Moderna to build vaccine factory in Africa

The biotech company expects to make its coronavirus vaccine and mRNA shots for other diseases at the planned plant, into which it will invest $500 million.

By Kristin Jensen • Oct. 7, 2021

US stocks up on COVID-19 antibody drugs amid shortage concerns

Deals with Regeneron and Eli Lilly will secure nearly 1.8 million additional doses of the companies' respective treatments over the next four months.

By Ned Pagliarulo • Sept. 15, 2021

CureVac scales back mRNA manufacturing for coronavirus vaccine

The German biotech, which announced disappointing results for its shot in June, said the move was done in response to reduced demand. 

By Shoshana Dubnow • Updated Sept. 15, 2021

Moderna expands mRNA vaccine supply in deal with new biotech producer

The company has previously said it could make up to 3 billion vaccine doses in 2022, depending on how booster shots are authorized.

By Shoshana Dubnow • Sept. 8, 2021

Eyeing future outbreaks, Moderna partners with Canadian government on vaccine plant

While Canada has already secured more COVID-19 vaccine doses than it needs, the factory to be built is geared toward combating future pandemics.

By Jonathan Gardner • Aug. 10, 2021

Amgen, expecting higher demand for its medicines, to build plant in North Carolina

The biotech is also constructing a new factory in Ohio and, between the two, expects to investment nearly $1 billion over the next few years.

By Kristin Jensen • Aug. 4, 2021

A pharma merger's impact ripples across West Virginia as Viatris plant closes

One of the country's oldest and largest drug manufacturing plants shut down Saturday, a consequence of the 2019 merger between Mylan and Pfizer's Upjohn unit. The impact will be felt by a West Virginia city for years to come.

By Shoshana Dubnow • July 30, 2021

Bluebird preps for split by selling manufacturing plant to well-funded startup

The startup manufacturing specialist National Resilience, which raised $800 million when it launched last year, will pay Bluebird $110 million for the North Carolina facility, bringing its North American network up to 10.

By Kristin Jensen • July 29, 2021

BioNTech, WHO hatch plan to bring mRNA vaccines to Africa

Responding to criticism, the German biotech plans to develop a malaria shot and build manufacturing infrastructure on the continent. 

By Jonathan Gardner • July 26, 2021